Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions-Reference-Cited by-同舟云学术

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions

Published:2014-03-05 Issue:4 Volume:55 Page:496-506
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Amstutz Ursula¹²³⁴,Shear Neil H.⁵,Rieder Michael J.⁶,Hwang Soomi⁷,Fung Vincent⁷⁸⁹,Nakamura Hidefumi¹⁰,Connolly Mary B.³¹¹,Ito Shinya¹²,Carleton Bruce C.¹²³,

Affiliation:

1. Division of Translational Therapeutics; Department of Pediatrics; University of British Columbia; Vancouver British Columbia Canada

2. Pharmaceutical Outcomes Programme; British Columbia Children's Hospital; Vancouver British Columbia Canada

3. Child and Family Research Institute; Vancouver British Columbia Canada

4. Department of Clinical Chemistry; University of Bern and Inselspital University Hospital; Bern Switzerland

5. Dermatology, Clinical Pharmacology and Toxicology; Department of Medicine; Sunnybrook Health Sciences Centre; University of Toronto; Toronto ON Canada

6. Clinical Pharmacology; Departments of Medicine, Physiology, Pharmacology and Pediatrics; Schulich School of Medicine and Dentistry; University of Western Ontario; London ON Canada

7. Faculty of Pharmaceutical Sciences; University of British Columbia; Vancouver British Columbia Canada

8. Prohealth Clinical Research Centre; Vancouver British Columbia Canada

9. Departments of Family Medicine and Pathology and Laboratory Medicine; Faculty of Medicine; University of British Columbia; Vancouver British Columbia Canada

10. Division for Clinical Trials; Clinical Research Center; National Center for Child Health and Development; Tokyo Japan

11. Division of Neurology; Department of Pediatrics; British Columbia Children's Hospital and University of British Columbia; Vancouver British Columbia Canada

12. Division of Clinical Pharmacology and Toxicology; Department of Pediatrics; The Hospital for Sick Children; University of Toronto; Toronto ON Canada

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.12564/fullpdf

Reference60 articles.

1. Novartis Pharmaceuticals Corporation Tegretol ® [prescribing information] http://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf

2. Novartis Pharmaceuticals Canada Inc TEGRETOL [Product Monograph] http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php

3. National Clinical Guideline Centre The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care (Clinical Guideline CG137, January 2012) http://publications.nice.org.uk/the-epilepsies-the-diagnosis-and-management-of-the-epilepsies-in-adults-and-children-in-primary-and-cg137

4. Canadian Agency for Drugs and Technologies in Health Pharmacological Treatments in Patients with Epilepsy: Guidelines http://www.cadth.ca/media/pdf/htis/April-2011/K0338_Guidelines_for_Treatment_of_Epilepsy_final.pdf

5. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024;Ambrosio;Neurochem Res,2002

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haplotype Analysis Reveals Pleiotropic Disease Associations in the HLA Region;2024-07-31

2. Risk factors for drug hypersensitivity reactions in children;Italian Journal of Pediatrics;2024-07-15

3. Severe cutaneous adverse reactions;Nature Reviews Disease Primers;2024-04-25

4. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs;European Journal of Human Genetics;2024-04-03

5. Relationships between acute generalized eruptive pustulosis, age, sex, primary disease, and prescription medications: Further analysis of the Japanese Adverse Drug Event Report database;Heliyon;2024-04